<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776919</url>
  </required_header>
  <id_info>
    <org_study_id>114677</org_study_id>
    <nct_id>NCT00776919</nct_id>
  </id_info>
  <brief_title>Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, Double-Blind, Controlled Study to evaluate the Safety and Efficacy of a
      clindamycin / benzoyl peroxide gel in Subjects with Acne Vulgaris
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, randomized, double-blind, comparator and vehicle-controlled study in subjects
      with acne vulgaris. Approximately 1320 subjects will be enrolled. Subjects will be randomized
      to 1 of 4 parallel study groups in a 1:1:1:1 ratio (clindamycin / benzoyl peroxide
      gel:clindamycin gel:BPO gel:vehicle gel).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>During each study visit, investigators/assessors evaluated acne severity of the participants' faces using the ISGA scale: 0=clear skin with no lesions (L); 1=almost clear, rare non-inflammatory L; 2=mild, some non-inflammatory L with no more than a few inflammatory L, no nodular L; 3=moderate, many non-inflammatory L, may have some inflammatory L, but no more than 1 small nodular L; 4=severe, many non-inflammatory and inflammatory L, but no more than a few nodular L; 5=very severe, many non-inflammatory and inflammatory L, and more than a few nodular L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline (BL) to Week 12 in Inflammatory Lesion Counts</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>During each study visit, trained study personnel at every investigational center assessed the inflammatory (pustules [small inflamed elevation of the skin that is filled with pus], papules [solid elevation of skin with no visible fluid], nodules [larger than papules with significant depth]) lesion counts for each participant. Each type of lesion was counted separately, and counts were taken from the face (including forehead, nose, cheeks, and chin). Missing values were imputed using the last observation carried forward (LOCF) method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline to Week 12 in Non-inflammatory Lesion Counts</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>During each study visit, trained study personnel at every investigational center assessed the non-inflammatory (open comedones [blackheads] and closed comedones [whiteheads]) lesion counts for each participant. Each type of lesion was counted separately, and counts were taken from the face (including forehead, nose, cheeks, and chin).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline to Week 12 in Total Lesion Counts</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>During each study visit, trained study personnel at every investigational center assessed the inflammatory (pustules, papules, nodules) and non-inflammatory (open and closed comedones) lesion counts for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face (including forehead, nose, cheeks, and chin). Total lesion counts were calculated as the sum of the inflammatory and non-inflammatory lesion counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline to Week 12 in Lesion Counts (Total, Inflammatory, and Non-inflammatory)</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>During each study visit, trained study personnel at every investigational center assessed the inflammatory (pustules, papules, nodules) and non-inflammatory (open and closed comedones) lesion counts for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face (including forehead, nose, cheeks, and chin). Total lesion counts were calculated as the sum of the inflammatory and non-inflammatory lesion counts. Percent change from Baseline to Week 12 was calculated as the value at Week 12 minus the value at Baseline divided by the Baseline value * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had a Subject Global Assessment (SGA) Score of 0 or 1 at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>During each study visit, participants evaluated their facial acne (excluding the scalp) using the SGA scale: 0=free of acne, with only an occasional blackhead/whitehead; 1=several blackheads/whiteheads and small pimples, no tender deep-seated bumps/cysts; 2=several to many blackheads/whiteheads and small to medium-sized pimples, one deep-seated bump/cyst; 3=many blackheads/whiteheads, many medium- to large-sized pimples, few deep-seated bumps/cysts; 4=presence of blackheads/whiteheads, several to many medium- to large-sized pimples, deep-seated bumps/cysts dominate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had an ISGA Score of 0 or 1 at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>During each study visit, investigators/assessors evaluated the acne severity of participants' faces using the ISGA scal: 0=clear skin with no lesions (L); 1=almost clear, rare non-inflammatory L; 2=mild, some non-inflammatory L with no more than a few inflammatory L, no nodular L; 3=moderate, many non-inflammatory L, may have some inflammatory L, but no more than 1 small nodular L; 4=severe, many non-inflammatory and inflammatory L, but no more than a few nodular L; 5=very severe, many non-inflammatory and inflammatory L, and more than a few nodular L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 12 in Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Systolic and diastolic blood pressure were measured at Baseline and Week 12 (end of study). Mean change from Baseline was calculated as the mean value at Week 12 minus the mean value at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 12 in Temperature</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Temperature was measured at Baseline and Week 12 (end of study). Mean change from Baseline was calculated as the mean value at Week 12 minus the mean value at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 12 in Pulse Rate</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <description>Pulse rate was measured at Baseline and Week 12 (end of study). Mean change from Baseline was calculated as the mean value at Week 12 minus the mean value at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Erythema, Dryness, and Peeling</measure>
    <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
    <description>Erythema (Er, redness), dryness (Dr), and peeling (Pn), were evaluated independently by the investigator as: 0 (absent)=no Er, Dr, or Pn; 1 (slight)=faint red/pink coloration (col.), barely perceptible Dr with no flakes or fissure, mild localized Pn; 2 (mild)=light red/pink col., perceptible Dr with no flakes/fissure, mild and diffuse Pn; 3 (moderate)=medium red col., easily noted Dr and flakes but no fissure; 4 (severe)=beet red col., Dr with flakes and fissure, prominent dense Pn. Change from Baseline was calculated as the value at Weeks 2, 4, 8, and 12 minus the the value at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Itching and Burning/Stinging</measure>
    <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
    <description>Itching and burning/stinging (piercing pain) were evaluated independently by the investigator as: 0 (none)=normal, no discomfort; 1 (slight)=noticeable discomfort that caused intermittent awareness; 2 (moderate)=noticeable discomfort that caused intermittent awareness and interfered occasionally with normal daily activities; 3 (strong)=definite continuous discomfort that interfered with normal daily activities. Change from Baseline was calculated as the value at Weeks 2, 4, 8, and 12 minus the value at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Duration of Study Product Use</measure>
    <time_frame>Baseline (Day 1) through Week 12</time_frame>
    <description>Mean duration of study product use was calculated as the average total duration inclusive of missed applications of the study product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting the Indicated Treatment-emergent Adverse Events (AEs) Resulting in Study Product Discontinuation</measure>
    <time_frame>Baseline (Day 1) through Week 12</time_frame>
    <description>An AE included, but was not limited to, any clinically significant worsening of a pre-existing condition; an event occurring from overdose (i.e., a dose higher than that indicated in the protocol) of the study product, whether accidental or intentional; an event occurring from abuse (e.g., use for nonstudy reasons) of the study product; or an event that was associated with the discontinuation of the use of the study product.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1315</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clindamycin / benzoyl peroxide gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BPO gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin / benzoyl peroxide gel</intervention_name>
    <description>Once a day application to the face</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin gel</intervention_name>
    <description>Once a day application to the face</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPO gel</intervention_name>
    <description>Once a day application to the face</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle gel</intervention_name>
    <description>Once a day application to the face</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be 12 to 45 years of age, inclusive, and in good general health.

          -  Clinical diagnosis of acne vulgaris

          -  Females of childbearing potential participating in the study must agree to use a
             medically acceptable method of contraception while receiving protocol-assigned
             product.

          -  Have the ability and willingness to follow all study procedures, attend all scheduled
             visits, and successfully complete the study.

          -  Have the ability to understand and sign a written informed consent form, which must be
             completed prior to study specific tasks being performed. Subjects under the legal age
             of consent in the state/province/country where the study is conducted must provide
             assent and have the written informed consent of a parent or guardian.

        Exclusion Criteria:

          -  Are pregnant or breast-feeding.

          -  Have a history or presence of other conditions that may increase the risk of the
             subject participating in the study and/or affect the evaluated outcomes.

          -  Used topical antibiotics on the face or used systemic antibiotics within the past 2
             weeks.

          -  Used topical corticosteroids on the face or systemic corticosteroids within the past 4
             weeks. Use of inhaled, intra-articular, or intra-lesional steroids other than for
             facial acne is acceptable.

          -  Used systemic retinoids within the past 6 months or topical retinoids within the past
             6 weeks.

          -  Received treatment with estrogens (including oral, implanted, injected and topical
             contraceptives), androgens, or anti-androgenic agents for 12 weeks or less immediately
             prior to starting study product. Subjects who have been treated with estrogens, as
             described above, androgens, or anti-androgenic agents for more than 12 consecutive
             weeks prior to start of study product are allowed to enroll as long as they do not
             expect to change dose, drug, or discontinue use during the study.

          -  Used topical anti-acne medications (eg, BPO, azelaic acid, resorcinol, salicylates,
             etc.) within the past 2 weeks.

          -  Used abradents or facial procedures, within the past 2 weeks.

          -  Use medications that may exacerbate acne.

          -  Have a known hypersensitivity or have had previous allergic reaction to any of the
             active components, lincomycin, or excipients of the study product.

          -  Used any investigational therapy within the past 4 weeks, or currently participating
             in another clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego, Div. of Pediatric &amp; Adolescents Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Laser Institute for Dermatology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherry Creek Research, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, Inc.</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Cosmetic Medicine and Research Institute</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology &amp; Vein Research Center, LLC</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKINQRI</name>
      <address>
        <city>Lincolnshire</city>
        <state>Illinois</state>
        <zip>60069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Skin Centre</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Rochester, PC</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch Center of New York</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center, PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Center for Dermatology</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology and Skin Care Center FXM Research International</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Moguel's Clinic/FXM Research International</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guildford Dermatology Specialist</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrial Research</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research, Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRDQ Centre de Recherche Dermatologique du Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St. John's</city>
        <zip>NL A1B 3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belize</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Eichenfield LF, Alió Sáenz AB. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study. J Drugs Dermatol. 2011 Dec;10(12):1382-96.</citation>
    <PMID>22134562</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <results_first_submitted>December 21, 2011</results_first_submitted>
  <results_first_submitted_qc>December 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2012</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114677</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114677</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114677</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114677</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114677</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114677</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114677</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Duac Low-dose (LD) Gel</title>
          <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Clindamycin Gel</title>
          <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>BPO Gel</title>
          <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Vehicle Gel</title>
          <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="327"/>
                <participants group_id="P2" count="328"/>
                <participants group_id="P3" count="328"/>
                <participants group_id="P4" count="332"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="295"/>
                <participants group_id="P3" count="296"/>
                <participants group_id="P4" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Lack of Efficacy/Lost Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duac Low-dose (LD) Gel</title>
          <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Clindamycin Gel</title>
          <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>BPO Gel</title>
          <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Vehicle Gel</title>
          <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="327"/>
            <count group_id="B2" value="328"/>
            <count group_id="B3" value="328"/>
            <count group_id="B4" value="332"/>
            <count group_id="B5" value="1315"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.0" spread="7.0"/>
                    <measurement group_id="B2" value="20.2" spread="6.9"/>
                    <measurement group_id="B3" value="20.6" spread="7.1"/>
                    <measurement group_id="B4" value="20.7" spread="7.4"/>
                    <measurement group_id="B5" value="20.4" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="210"/>
                    <measurement group_id="B5" value="795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="122"/>
                    <measurement group_id="B5" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="274"/>
                    <measurement group_id="B3" value="251"/>
                    <measurement group_id="B4" value="258"/>
                    <measurement group_id="B5" value="1042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12</title>
        <description>During each study visit, investigators/assessors evaluated acne severity of the participants' faces using the ISGA scale: 0=clear skin with no lesions (L); 1=almost clear, rare non-inflammatory L; 2=mild, some non-inflammatory L with no more than a few inflammatory L, no nodular L; 3=moderate, many non-inflammatory L, may have some inflammatory L, but no more than 1 small nodular L; 4=severe, many non-inflammatory and inflammatory L, but no more than a few nodular L; 5=very severe, many non-inflammatory and inflammatory L, and more than a few nodular L.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who were randomized to and received at least 1 application of study product. Participants with missing Week 12 evaluations were considered failures. Failures are defined as those participants with a 1-grade improvement, no improvement, or a worsening.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12</title>
          <description>During each study visit, investigators/assessors evaluated acne severity of the participants' faces using the ISGA scale: 0=clear skin with no lesions (L); 1=almost clear, rare non-inflammatory L; 2=mild, some non-inflammatory L with no more than a few inflammatory L, no nodular L; 3=moderate, many non-inflammatory L, may have some inflammatory L, but no more than 1 small nodular L; 4=severe, many non-inflammatory and inflammatory L, but no more than a few nodular L; 5=very severe, many non-inflammatory and inflammatory L, and more than a few nodular L.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who were randomized to and received at least 1 application of study product. Participants with missing Week 12 evaluations were considered failures. Failures are defined as those participants with a 1-grade improvement, no improvement, or a worsening.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="328"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline (BL) to Week 12 in Inflammatory Lesion Counts</title>
        <description>During each study visit, trained study personnel at every investigational center assessed the inflammatory (pustules [small inflamed elevation of the skin that is filled with pus], papules [solid elevation of skin with no visible fluid], nodules [larger than papules with significant depth]) lesion counts for each participant. Each type of lesion was counted separately, and counts were taken from the face (including forehead, nose, cheeks, and chin). Missing values were imputed using the last observation carried forward (LOCF) method.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>ITT Population. Participants who missed &gt;=16 days of treatment or reported lost medication and never began treatment were excluded from the analysis. In the LOCF method, the last available observation, including BL, was used to estimate subsequent missing data points.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (BL) to Week 12 in Inflammatory Lesion Counts</title>
          <description>During each study visit, trained study personnel at every investigational center assessed the inflammatory (pustules [small inflamed elevation of the skin that is filled with pus], papules [solid elevation of skin with no visible fluid], nodules [larger than papules with significant depth]) lesion counts for each participant. Each type of lesion was counted separately, and counts were taken from the face (including forehead, nose, cheeks, and chin). Missing values were imputed using the last observation carried forward (LOCF) method.</description>
          <population>ITT Population. Participants who missed &gt;=16 days of treatment or reported lost medication and never began treatment were excluded from the analysis. In the LOCF method, the last available observation, including BL, was used to estimate subsequent missing data points.</population>
          <units>lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="323"/>
                <count group_id="O4" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2" spread="10.4"/>
                    <measurement group_id="O2" value="-15.6" spread="11.6"/>
                    <measurement group_id="O3" value="-16.8" spread="11.5"/>
                    <measurement group_id="O4" value="-13.1" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on an analysis of covariance (ANCOVA) with factors of treatment, center, and interaction of treatment-center. If the treatment-center interaction was not significant at the 0.1 level, this interaction was excluded from the ANCOVA model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>Based on an analysis of covariance (ANCOVA) with factors of treatment, center, and interaction of treatment-center. If the treatment-center interaction was not significant at the 0.1 level, this interaction was excluded from the ANCOVA model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on an analysis of covariance (ANCOVA) with factors of treatment, center, and interaction of treatment-center. If the treatment-center interaction was not significant at the 0.1 level, this interaction was excluded from the ANCOVA model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Week 12 in Non-inflammatory Lesion Counts</title>
        <description>During each study visit, trained study personnel at every investigational center assessed the non-inflammatory (open comedones [blackheads] and closed comedones [whiteheads]) lesion counts for each participant. Each type of lesion was counted separately, and counts were taken from the face (including forehead, nose, cheeks, and chin).</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>ITT Population. Participants who missed &gt;=16 days of treatment or who reported they had lost their medication and never began treatment were excluded from the analysis. Missing values for all other participants were imputed using the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in Non-inflammatory Lesion Counts</title>
          <description>During each study visit, trained study personnel at every investigational center assessed the non-inflammatory (open comedones [blackheads] and closed comedones [whiteheads]) lesion counts for each participant. Each type of lesion was counted separately, and counts were taken from the face (including forehead, nose, cheeks, and chin).</description>
          <population>ITT Population. Participants who missed &gt;=16 days of treatment or who reported they had lost their medication and never began treatment were excluded from the analysis. Missing values for all other participants were imputed using the LOCF method.</population>
          <units>lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="323"/>
                <count group_id="O4" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.8" spread="20.1"/>
                    <measurement group_id="O2" value="-19.8" spread="19.8"/>
                    <measurement group_id="O3" value="-22.2" spread="17.6"/>
                    <measurement group_id="O4" value="-14.8" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on an analysis of covariance (ANCOVA) with factors of treatment, center, and interaction of treatment-center. If the treatment-center interaction was not significant at the 0.1 level, this interaction was excluded from the ANCOVA model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.102</p_value>
            <p_value_desc>Based on an analysis of covariance (ANCOVA) with factors of treatment, center, and interaction of treatment-center. If the treatment-center interaction was not significant at the 0.1 level, this interaction was excluded from the ANCOVA model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on an analysis of covariance (ANCOVA) with factors of treatment, center, and interaction of treatment-center. If the treatment-center interaction was not significant at the 0.1 level, this interaction was excluded from the ANCOVA model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Week 12 in Total Lesion Counts</title>
        <description>During each study visit, trained study personnel at every investigational center assessed the inflammatory (pustules, papules, nodules) and non-inflammatory (open and closed comedones) lesion counts for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face (including forehead, nose, cheeks, and chin). Total lesion counts were calculated as the sum of the inflammatory and non-inflammatory lesion counts.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>ITT Population. Participants who missed &gt;=16 days of treatment or who reported they had lost their medication and never began treatment were excluded from the analysis. Missing values for all other participants were imputed using the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in Total Lesion Counts</title>
          <description>During each study visit, trained study personnel at every investigational center assessed the inflammatory (pustules, papules, nodules) and non-inflammatory (open and closed comedones) lesion counts for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face (including forehead, nose, cheeks, and chin). Total lesion counts were calculated as the sum of the inflammatory and non-inflammatory lesion counts.</description>
          <population>ITT Population. Participants who missed &gt;=16 days of treatment or who reported they had lost their medication and never began treatment were excluded from the analysis. Missing values for all other participants were imputed using the LOCF method.</population>
          <units>lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="323"/>
                <count group_id="O4" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.0" spread="27.1"/>
                    <measurement group_id="O2" value="-35.5" spread="27.1"/>
                    <measurement group_id="O3" value="-39.0" spread="25.0"/>
                    <measurement group_id="O4" value="-27.8" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on an analysis of covariance (ANCOVA) with factors of treatment, center, and interaction of treatment-center. If the treatment-center interaction was not significant at the 0.1 level, this interaction was excluded from the ANCOVA model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <p_value_desc>Based on an analysis of covariance (ANCOVA) with factors of treatment, center, and interaction of treatment-center. If the treatment-center interaction was not significant at the 0.1 level, this interaction was excluded from the ANCOVA model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on an analysis of covariance (ANCOVA) with factors of treatment, center, and interaction of treatment-center. If the treatment-center interaction was not significant at the 0.1 level, this interaction was excluded from the ANCOVA model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline to Week 12 in Lesion Counts (Total, Inflammatory, and Non-inflammatory)</title>
        <description>During each study visit, trained study personnel at every investigational center assessed the inflammatory (pustules, papules, nodules) and non-inflammatory (open and closed comedones) lesion counts for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face (including forehead, nose, cheeks, and chin). Total lesion counts were calculated as the sum of the inflammatory and non-inflammatory lesion counts. Percent change from Baseline to Week 12 was calculated as the value at Week 12 minus the value at Baseline divided by the Baseline value * 100.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>ITT Population. Participants who missed &gt;=16 days of treatment or who reported they had lost their medication and never began treatment were excluded from the analysis. Missing values for all other participants were imputed using the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline to Week 12 in Lesion Counts (Total, Inflammatory, and Non-inflammatory)</title>
          <description>During each study visit, trained study personnel at every investigational center assessed the inflammatory (pustules, papules, nodules) and non-inflammatory (open and closed comedones) lesion counts for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face (including forehead, nose, cheeks, and chin). Total lesion counts were calculated as the sum of the inflammatory and non-inflammatory lesion counts. Percent change from Baseline to Week 12 was calculated as the value at Week 12 minus the value at Baseline divided by the Baseline value * 100.</description>
          <population>ITT Population. Participants who missed &gt;=16 days of treatment or who reported they had lost their medication and never began treatment were excluded from the analysis. Missing values for all other participants were imputed using the LOCF method.</population>
          <units>Percent change in lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="323"/>
                <count group_id="O4" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammatory Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68.9" spread="29.6"/>
                    <measurement group_id="O2" value="-58.1" spread="35.8"/>
                    <measurement group_id="O3" value="-61.8" spread="31.5"/>
                    <measurement group_id="O4" value="-48.8" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-inflammatory Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.9" spread="32.2"/>
                    <measurement group_id="O2" value="-43.3" spread="39.6"/>
                    <measurement group_id="O3" value="-50.8" spread="33.5"/>
                    <measurement group_id="O4" value="-34.0" spread="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.8" spread="28.0"/>
                    <measurement group_id="O2" value="-49.2" spread="33.8"/>
                    <measurement group_id="O3" value="-55.5" spread="28.8"/>
                    <measurement group_id="O4" value="-40.4" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had a Subject Global Assessment (SGA) Score of 0 or 1 at Week 12</title>
        <description>During each study visit, participants evaluated their facial acne (excluding the scalp) using the SGA scale: 0=free of acne, with only an occasional blackhead/whitehead; 1=several blackheads/whiteheads and small pimples, no tender deep-seated bumps/cysts; 2=several to many blackheads/whiteheads and small to medium-sized pimples, one deep-seated bump/cyst; 3=many blackheads/whiteheads, many medium- to large-sized pimples, few deep-seated bumps/cysts; 4=presence of blackheads/whiteheads, several to many medium- to large-sized pimples, deep-seated bumps/cysts dominate.</description>
        <time_frame>Week 12</time_frame>
        <population>ITT Population. Participants with missing Week 12 evaluations were considered failures. Failures were defined as those participants with an SGA score &gt;=2.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had a Subject Global Assessment (SGA) Score of 0 or 1 at Week 12</title>
          <description>During each study visit, participants evaluated their facial acne (excluding the scalp) using the SGA scale: 0=free of acne, with only an occasional blackhead/whitehead; 1=several blackheads/whiteheads and small pimples, no tender deep-seated bumps/cysts; 2=several to many blackheads/whiteheads and small to medium-sized pimples, one deep-seated bump/cyst; 3=many blackheads/whiteheads, many medium- to large-sized pimples, few deep-seated bumps/cysts; 4=presence of blackheads/whiteheads, several to many medium- to large-sized pimples, deep-seated bumps/cysts dominate.</description>
          <population>ITT Population. Participants with missing Week 12 evaluations were considered failures. Failures were defined as those participants with an SGA score &gt;=2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="328"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="189"/>
                    <measurement group_id="O4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had an ISGA Score of 0 or 1 at Week 12</title>
        <description>During each study visit, investigators/assessors evaluated the acne severity of participants' faces using the ISGA scal: 0=clear skin with no lesions (L); 1=almost clear, rare non-inflammatory L; 2=mild, some non-inflammatory L with no more than a few inflammatory L, no nodular L; 3=moderate, many non-inflammatory L, may have some inflammatory L, but no more than 1 small nodular L; 4=severe, many non-inflammatory and inflammatory L, but no more than a few nodular L; 5=very severe, many non-inflammatory and inflammatory L, and more than a few nodular L.</description>
        <time_frame>Week 12</time_frame>
        <population>ITT Population. Participants with missing Week 12 evaluations were considered failures. Failures were defined as those participants with an ISGA score &gt;=2.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had an ISGA Score of 0 or 1 at Week 12</title>
          <description>During each study visit, investigators/assessors evaluated the acne severity of participants' faces using the ISGA scal: 0=clear skin with no lesions (L); 1=almost clear, rare non-inflammatory L; 2=mild, some non-inflammatory L with no more than a few inflammatory L, no nodular L; 3=moderate, many non-inflammatory L, may have some inflammatory L, but no more than 1 small nodular L; 4=severe, many non-inflammatory and inflammatory L, but no more than a few nodular L; 5=very severe, many non-inflammatory and inflammatory L, and more than a few nodular L.</description>
          <population>ITT Population. Participants with missing Week 12 evaluations were considered failures. Failures were defined as those participants with an ISGA score &gt;=2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="328"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="116"/>
                    <measurement group_id="O4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 12 in Systolic and Diastolic Blood Pressure</title>
        <description>Systolic and diastolic blood pressure were measured at Baseline and Week 12 (end of study). Mean change from Baseline was calculated as the mean value at Week 12 minus the mean value at Baseline.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>ITT Population. Only those participants with data available at both Baseline and Week 12 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in Systolic and Diastolic Blood Pressure</title>
          <description>Systolic and diastolic blood pressure were measured at Baseline and Week 12 (end of study). Mean change from Baseline was calculated as the mean value at Week 12 minus the mean value at Baseline.</description>
          <population>ITT Population. Only those participants with data available at both Baseline and Week 12 were analyzed.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="305"/>
                <count group_id="O4" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="10"/>
                    <measurement group_id="O2" value="0" spread="11"/>
                    <measurement group_id="O3" value="0" spread="12"/>
                    <measurement group_id="O4" value="0" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="8"/>
                    <measurement group_id="O2" value="1" spread="9"/>
                    <measurement group_id="O3" value="0" spread="8"/>
                    <measurement group_id="O4" value="0" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 12 in Temperature</title>
        <description>Temperature was measured at Baseline and Week 12 (end of study). Mean change from Baseline was calculated as the mean value at Week 12 minus the mean value at Baseline.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>ITT Population. Only those participants with data available at both Baseline and Week 12 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in Temperature</title>
          <description>Temperature was measured at Baseline and Week 12 (end of study). Mean change from Baseline was calculated as the mean value at Week 12 minus the mean value at Baseline.</description>
          <population>ITT Population. Only those participants with data available at both Baseline and Week 12 were analyzed.</population>
          <units>Degrees centigrade</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="305"/>
                <count group_id="O4" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.4"/>
                    <measurement group_id="O2" value="0.0" spread="0.4"/>
                    <measurement group_id="O3" value="0.0" spread="0.4"/>
                    <measurement group_id="O4" value="0.0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 12 in Pulse Rate</title>
        <description>Pulse rate was measured at Baseline and Week 12 (end of study). Mean change from Baseline was calculated as the mean value at Week 12 minus the mean value at Baseline.</description>
        <time_frame>Baseline (Day 1) and Week 12</time_frame>
        <population>ITT Population. Only those participants with data available at both Baseline and Week 12 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 12 in Pulse Rate</title>
          <description>Pulse rate was measured at Baseline and Week 12 (end of study). Mean change from Baseline was calculated as the mean value at Week 12 minus the mean value at Baseline.</description>
          <population>ITT Population. Only those participants with data available at both Baseline and Week 12 were analyzed.</population>
          <units>Beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="10"/>
                    <measurement group_id="O2" value="2" spread="11"/>
                    <measurement group_id="O3" value="2" spread="9"/>
                    <measurement group_id="O4" value="2" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Erythema, Dryness, and Peeling</title>
        <description>Erythema (Er, redness), dryness (Dr), and peeling (Pn), were evaluated independently by the investigator as: 0 (absent)=no Er, Dr, or Pn; 1 (slight)=faint red/pink coloration (col.), barely perceptible Dr with no flakes or fissure, mild localized Pn; 2 (mild)=light red/pink col., perceptible Dr with no flakes/fissure, mild and diffuse Pn; 3 (moderate)=medium red col., easily noted Dr and flakes but no fissure; 4 (severe)=beet red col., Dr with flakes and fissure, prominent dense Pn. Change from Baseline was calculated as the value at Weeks 2, 4, 8, and 12 minus the the value at Baseline.</description>
        <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
        <population>ITT Population. Only those participants with data available at both Baseline and the indicated assessment week were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Erythema, Dryness, and Peeling</title>
          <description>Erythema (Er, redness), dryness (Dr), and peeling (Pn), were evaluated independently by the investigator as: 0 (absent)=no Er, Dr, or Pn; 1 (slight)=faint red/pink coloration (col.), barely perceptible Dr with no flakes or fissure, mild localized Pn; 2 (mild)=light red/pink col., perceptible Dr with no flakes/fissure, mild and diffuse Pn; 3 (moderate)=medium red col., easily noted Dr and flakes but no fissure; 4 (severe)=beet red col., Dr with flakes and fissure, prominent dense Pn. Change from Baseline was calculated as the value at Weeks 2, 4, 8, and 12 minus the the value at Baseline.</description>
          <population>ITT Population. Only those participants with data available at both Baseline and the indicated assessment week were analyzed.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema, Week 2, n=298, 302, 306, 306</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.63"/>
                    <measurement group_id="O2" value="-0.01" spread="0.58"/>
                    <measurement group_id="O3" value="-0.07" spread="0.56"/>
                    <measurement group_id="O4" value="-0.02" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema, Week 4, n=298, 300, 299, 306</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.66"/>
                    <measurement group_id="O2" value="-0.07" spread="0.64"/>
                    <measurement group_id="O3" value="-0.08" spread="0.67"/>
                    <measurement group_id="O4" value="-0.06" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema, Week 8, n=297, 296, 294, 293</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.71"/>
                    <measurement group_id="O2" value="-0.08" spread="0.67"/>
                    <measurement group_id="O3" value="-0.15" spread="0.68"/>
                    <measurement group_id="O4" value="-0.08" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema, Week 12, n=297, 296, 296, 294</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.66"/>
                    <measurement group_id="O2" value="-0.18" spread="0.63"/>
                    <measurement group_id="O3" value="-0.17" spread="0.67"/>
                    <measurement group_id="O4" value="-0.13" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness, Week 2, n=298, 302, 306, 306</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.54"/>
                    <measurement group_id="O2" value="0.03" spread="0.48"/>
                    <measurement group_id="O3" value="0.09" spread="0.61"/>
                    <measurement group_id="O4" value="0.04" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness, Week 4, n=298, 300, 299, 306</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.58"/>
                    <measurement group_id="O2" value="-0.02" spread="0.51"/>
                    <measurement group_id="O3" value="0.08" spread="0.55"/>
                    <measurement group_id="O4" value="0.00" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness, Week 8, n=297, 296, 294, 293</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.53"/>
                    <measurement group_id="O2" value="-0.02" spread="0.58"/>
                    <measurement group_id="O3" value="0.05" spread="0.57"/>
                    <measurement group_id="O4" value="0.02" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness, Week 12, n=297, 296, 296, 294</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.62"/>
                    <measurement group_id="O2" value="-0.10" spread="0.53"/>
                    <measurement group_id="O3" value="-0.01" spread="0.57"/>
                    <measurement group_id="O4" value="-0.04" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peeling, Week 2, n=298, 302, 306, 306</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.43"/>
                    <measurement group_id="O2" value="0.02" spread="0.36"/>
                    <measurement group_id="O3" value="0.08" spread="0.51"/>
                    <measurement group_id="O4" value="0.02" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peeling, Week 4, n=298, 300, 299, 306</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.39"/>
                    <measurement group_id="O2" value="0.00" spread="0.36"/>
                    <measurement group_id="O3" value="0.01" spread="0.39"/>
                    <measurement group_id="O4" value="0.00" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peeling, Week 8, n=297, 296, 294, 293</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.41"/>
                    <measurement group_id="O2" value="-0.01" spread="0.42"/>
                    <measurement group_id="O3" value="-0.01" spread="0.40"/>
                    <measurement group_id="O4" value="0.00" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peeling, Week 12, n=297, 296, 296, 294</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.44"/>
                    <measurement group_id="O2" value="-0.06" spread="0.40"/>
                    <measurement group_id="O3" value="-0.02" spread="0.50"/>
                    <measurement group_id="O4" value="-0.04" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Itching and Burning/Stinging</title>
        <description>Itching and burning/stinging (piercing pain) were evaluated independently by the investigator as: 0 (none)=normal, no discomfort; 1 (slight)=noticeable discomfort that caused intermittent awareness; 2 (moderate)=noticeable discomfort that caused intermittent awareness and interfered occasionally with normal daily activities; 3 (strong)=definite continuous discomfort that interfered with normal daily activities. Change from Baseline was calculated as the value at Weeks 2, 4, 8, and 12 minus the value at Baseline.</description>
        <time_frame>Baseline; Weeks 2, 4, 8, and 12</time_frame>
        <population>ITT Population. Only those participants with data available at both Baseline and the indicated assessment week were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Itching and Burning/Stinging</title>
          <description>Itching and burning/stinging (piercing pain) were evaluated independently by the investigator as: 0 (none)=normal, no discomfort; 1 (slight)=noticeable discomfort that caused intermittent awareness; 2 (moderate)=noticeable discomfort that caused intermittent awareness and interfered occasionally with normal daily activities; 3 (strong)=definite continuous discomfort that interfered with normal daily activities. Change from Baseline was calculated as the value at Weeks 2, 4, 8, and 12 minus the value at Baseline.</description>
          <population>ITT Population. Only those participants with data available at both Baseline and the indicated assessment week were analyzed.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Itching, Week 2, n=297, 301, 305, 305</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.67"/>
                    <measurement group_id="O2" value="-0.18" spread="0.67"/>
                    <measurement group_id="O3" value="-0.04" spread="0.64"/>
                    <measurement group_id="O4" value="-0.06" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching, Week 4, n=298, 299, 299, 305</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.67"/>
                    <measurement group_id="O2" value="-0.18" spread="0.68"/>
                    <measurement group_id="O3" value="-0.07" spread="0.68"/>
                    <measurement group_id="O4" value="-0.10" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching, Week 8, n=297, 295, 293, 291</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.75"/>
                    <measurement group_id="O2" value="-0.24" spread="0.69"/>
                    <measurement group_id="O3" value="-0.08" spread="0.68"/>
                    <measurement group_id="O4" value="-0.08" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching, Week 12, n=297, 295, 294, 293</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.70"/>
                    <measurement group_id="O2" value="-0.28" spread="0.67"/>
                    <measurement group_id="O3" value="-0.13" spread="0.72"/>
                    <measurement group_id="O4" value="-0.13" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning/Stinging, Week 2, n=297, 301, 305, 305</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.58"/>
                    <measurement group_id="O2" value="-0.06" spread="0.48"/>
                    <measurement group_id="O3" value="-0.02" spread="0.56"/>
                    <measurement group_id="O4" value="-0.05" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning/Stinging, Week 4, n=298, 2991, 299, 305</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.57"/>
                    <measurement group_id="O2" value="-0.09" spread="0.46"/>
                    <measurement group_id="O3" value="-0.05" spread="0.55"/>
                    <measurement group_id="O4" value="-0.02" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning/Stinging, Week 8, n=297, 295, 293, 291</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.57"/>
                    <measurement group_id="O2" value="-0.09" spread="0.46"/>
                    <measurement group_id="O3" value="-0.05" spread="0.55"/>
                    <measurement group_id="O4" value="-0.06" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning/Stinging, Week 12, n=297, 295, 294, 293</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.58"/>
                    <measurement group_id="O2" value="-0.13" spread="0.48"/>
                    <measurement group_id="O3" value="-0.04" spread="0.60"/>
                    <measurement group_id="O4" value="-0.04" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Duration of Study Product Use</title>
        <description>Mean duration of study product use was calculated as the average total duration inclusive of missed applications of the study product.</description>
        <time_frame>Baseline (Day 1) through Week 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Duration of Study Product Use</title>
          <description>Mean duration of study product use was calculated as the average total duration inclusive of missed applications of the study product.</description>
          <population>ITT Population</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="328"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="16.4"/>
                    <measurement group_id="O2" value="78.0" spread="17.9"/>
                    <measurement group_id="O3" value="78.0" spread="18.4"/>
                    <measurement group_id="O4" value="77.8" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting the Indicated Treatment-emergent Adverse Events (AEs) Resulting in Study Product Discontinuation</title>
        <description>An AE included, but was not limited to, any clinically significant worsening of a pre-existing condition; an event occurring from overdose (i.e., a dose higher than that indicated in the protocol) of the study product, whether accidental or intentional; an event occurring from abuse (e.g., use for nonstudy reasons) of the study product; or an event that was associated with the discontinuation of the use of the study product.</description>
        <time_frame>Baseline (Day 1) through Week 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Duac Low-dose (LD) Gel</title>
            <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clindamycin Gel</title>
            <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>BPO Gel</title>
            <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Gel</title>
            <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting the Indicated Treatment-emergent Adverse Events (AEs) Resulting in Study Product Discontinuation</title>
          <description>An AE included, but was not limited to, any clinically significant worsening of a pre-existing condition; an event occurring from overdose (i.e., a dose higher than that indicated in the protocol) of the study product, whether accidental or intentional; an event occurring from abuse (e.g., use for nonstudy reasons) of the study product; or an event that was associated with the discontinuation of the use of the study product.</description>
          <population>ITT Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="328"/>
                <count group_id="O4" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Application Site Dermatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Application Site Hypersensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Application Site Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Duac Low-dose (LD) Gel</title>
          <description>Duac LD gel (combination of 1% clindamycin phosphate and 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Clindamycin Gel</title>
          <description>Clindamycin gel (containing 1% clindamycin phosphate) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>BPO Gel</title>
          <description>Benzoyl peroxide (BPO) gel (containing 3% benzoyl peroxide) applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Vehicle Gel</title>
          <description>Matching vehicle gel without the active ingredients clinidamycin phosphate and benzoyl peroxide, applied once daily (in the morning or evening, but at approximately the same time each day) to the entire face for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron Deficiency Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Keratoconus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dental Caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Stomach Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Application Site Dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Application Site Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Application Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Application Site Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Application Site Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Application Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Application Site Photosensitivity Reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Application Site Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Drug Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Alveolar Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Arthritis Infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Body Tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Gingival Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Infectious Mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Otitis Externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tinea Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Mycotic Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Fractured Coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Joint Sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Limb Crushing Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Neck Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Post-Traumatic Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Testosterone Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic Naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Skin Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Attention Deficit/Hyperactivity Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa Uteri Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Breast Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst Ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Chloasma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Ingrowing Nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elective Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Mole Excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Tooth Extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="332"/>
              </event>
              <event>
                <sub_title>Wisdom Teeth Removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="332"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

